Comparison of bone mineral density of osteoporotic and osteopenia menopausal women treated with oral bisphosphonates before stopping the treatment and 1 year after drug holiday period
Background Osteoporosis is a skeletal and bone disorder characterized by bone fractures and decreased bone mineral density (BMD). Bisphosphonates have a great tendency to bind to minerals, and their long-term use can increase the risk of bone fragility in patients. Stopping bisphosphonates after a p...
Gespeichert in:
| Veröffentlicht in: | Clinical rheumatology 2024-04, Vol.43 (4), p.1375-1379 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1379 |
|---|---|
| container_issue | 4 |
| container_start_page | 1375 |
| container_title | Clinical rheumatology |
| container_volume | 43 |
| creator | Rizi, Marzieh Moradi Salari, Amirhossein Salesi, Mansour Rasooli, Laa’ya Karimifar, Mansoor |
| description | Background
Osteoporosis is a skeletal and bone disorder characterized by bone fractures and decreased bone mineral density (BMD). Bisphosphonates have a great tendency to bind to minerals, and their long-term use can increase the risk of bone fragility in patients. Stopping bisphosphonates after a period of time is called a drug holiday (DH). Recent evidence has shown that patients’ BMD may decrease again during DH. However, few studies have been done in this regard. In the present study, we compared the BMD of postmenopausal women during bisphosphonates treatment and 1 year after DH.
Material and methods
A total of 202 patients were selected with osteopenia (
n
= 95) and osteoporosis (
n
= 107); they had been treated with alendronate for 5 years (a rheumatologist confirmed the diagnosis of osteopenia and osteoporosis) and had undergone DH for 1 year. At the arrival of all patients, BMD was checked with the DXA (dual-energy X-ray absorptiometry) method using the 2007 American Explorer model Hologic device based on the Caucasian race. One year later, patients were reassessed for BMD by the same device.
Result
The analysis of femoral neck (FN) and lumbar spine (LS) T-score indices in the osteopenia and the osteoporosis groups showed reduction after DH, and the difference was statistically significant in both groups (
p
= 0.001). After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups (
p
= 0.001).
Conclusion
In general, it can be said that DH can reduce FN and LS T-scores. The results indicated a significant reduction in BMD after the DH period for both the osteoporosis and osteopenia groups in the early months. Also, the effect of DH in osteoporosis patients was more compared to the osteopenia individuals, which could have implications for their treatment approach, and also its effect on bone health.
Key Points
• The DH can reduce FN and LS T-scores
• The BMD reduced after the DH period for both the osteoporosis and osteopenia groups
• After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups |
| doi_str_mv | 10.1007/s10067-024-06906-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2926078099</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2958108334</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-553c45ae4d7c0501950645baca701ce10c6df29e686c51b36fa39b3420d6f33c3</originalsourceid><addsrcrecordid>eNqFksGOFCEURStG47SjP-DCkLiZTemjKKBYmo6OJpO40XWFglfdTLqgBCqT_pv5DNd-mfRUq4kLXQDhvXMvAW5VvaTwhgLIt6nMQtbQtDUIBaKWj6oNbVlbK9Wqx9UGpISaUdVdVM9SugWAplP0aXXBOtZK1vBN9X0bpllHl4InYSRD8Egm5zHqA7Hok8vHUz2kjGEOMWRniPb2XEDvNJnQh1kvqSjuQtmQHFFntOTO5T0JJ6fBpXkfTsOXTiIDjiEiSTnMs_M7kve4qoo8P_jTH_dH1JHoMWMkNi47sg8HZ_WRzBhdsM-rJ6M-JHxxXi-rrx_ef9l-rG8-X3_avrupDeMq15wz03KNrZUGOFDFQbR80EZLoAYpGGHHRqHohOF0YGLUTA2sbcCKkTHDLqur1XeO4duCKfeTSwYPB-0xLKlnlDNBy7vy_6KNagTIDpQq6Ou_0NuwRF8uUijeUegYawvVrJSJIaWIYz9HN-l47Cn0pwj0awT6EoH-IQK9LKJXZ-tlmND-lvz68wKwFUil5XcY_5z9D9ufkP3AyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2958108334</pqid></control><display><type>article</type><title>Comparison of bone mineral density of osteoporotic and osteopenia menopausal women treated with oral bisphosphonates before stopping the treatment and 1 year after drug holiday period</title><source>Springer Journals</source><creator>Rizi, Marzieh Moradi ; Salari, Amirhossein ; Salesi, Mansour ; Rasooli, Laa’ya ; Karimifar, Mansoor</creator><creatorcontrib>Rizi, Marzieh Moradi ; Salari, Amirhossein ; Salesi, Mansour ; Rasooli, Laa’ya ; Karimifar, Mansoor</creatorcontrib><description>Background
Osteoporosis is a skeletal and bone disorder characterized by bone fractures and decreased bone mineral density (BMD). Bisphosphonates have a great tendency to bind to minerals, and their long-term use can increase the risk of bone fragility in patients. Stopping bisphosphonates after a period of time is called a drug holiday (DH). Recent evidence has shown that patients’ BMD may decrease again during DH. However, few studies have been done in this regard. In the present study, we compared the BMD of postmenopausal women during bisphosphonates treatment and 1 year after DH.
Material and methods
A total of 202 patients were selected with osteopenia (
n
= 95) and osteoporosis (
n
= 107); they had been treated with alendronate for 5 years (a rheumatologist confirmed the diagnosis of osteopenia and osteoporosis) and had undergone DH for 1 year. At the arrival of all patients, BMD was checked with the DXA (dual-energy X-ray absorptiometry) method using the 2007 American Explorer model Hologic device based on the Caucasian race. One year later, patients were reassessed for BMD by the same device.
Result
The analysis of femoral neck (FN) and lumbar spine (LS) T-score indices in the osteopenia and the osteoporosis groups showed reduction after DH, and the difference was statistically significant in both groups (
p
= 0.001). After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups (
p
= 0.001).
Conclusion
In general, it can be said that DH can reduce FN and LS T-scores. The results indicated a significant reduction in BMD after the DH period for both the osteoporosis and osteopenia groups in the early months. Also, the effect of DH in osteoporosis patients was more compared to the osteopenia individuals, which could have implications for their treatment approach, and also its effect on bone health.
Key Points
• The DH can reduce FN and LS T-scores
• The BMD reduced after the DH period for both the osteoporosis and osteopenia groups
• After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups</description><identifier>ISSN: 0770-3198</identifier><identifier>EISSN: 1434-9949</identifier><identifier>DOI: 10.1007/s10067-024-06906-7</identifier><identifier>PMID: 38347325</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Alendronic acid ; Bisphosphonates ; Bone density ; bone health ; Bone mineral density ; drugs ; Dual energy X-ray absorptiometry ; femur ; Fractures ; lumbar spine ; Medicine ; Medicine & Public Health ; Original Article ; Osteopenia ; Osteoporosis ; Post-menopause ; postmenopause ; Rheumatology ; risk ; Spine (lumbar) ; Statistical analysis</subject><ispartof>Clinical rheumatology, 2024-04, Vol.43 (4), p.1375-1379</ispartof><rights>The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR) 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c359t-553c45ae4d7c0501950645baca701ce10c6df29e686c51b36fa39b3420d6f33c3</cites><orcidid>0000-0003-4688-991X ; 0000-0001-7108-6188 ; 0000-0001-7077-9652 ; 0000-0002-7542-7426 ; 0000-0003-4860-1174</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10067-024-06906-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10067-024-06906-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38347325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rizi, Marzieh Moradi</creatorcontrib><creatorcontrib>Salari, Amirhossein</creatorcontrib><creatorcontrib>Salesi, Mansour</creatorcontrib><creatorcontrib>Rasooli, Laa’ya</creatorcontrib><creatorcontrib>Karimifar, Mansoor</creatorcontrib><title>Comparison of bone mineral density of osteoporotic and osteopenia menopausal women treated with oral bisphosphonates before stopping the treatment and 1 year after drug holiday period</title><title>Clinical rheumatology</title><addtitle>Clin Rheumatol</addtitle><addtitle>Clin Rheumatol</addtitle><description>Background
Osteoporosis is a skeletal and bone disorder characterized by bone fractures and decreased bone mineral density (BMD). Bisphosphonates have a great tendency to bind to minerals, and their long-term use can increase the risk of bone fragility in patients. Stopping bisphosphonates after a period of time is called a drug holiday (DH). Recent evidence has shown that patients’ BMD may decrease again during DH. However, few studies have been done in this regard. In the present study, we compared the BMD of postmenopausal women during bisphosphonates treatment and 1 year after DH.
Material and methods
A total of 202 patients were selected with osteopenia (
n
= 95) and osteoporosis (
n
= 107); they had been treated with alendronate for 5 years (a rheumatologist confirmed the diagnosis of osteopenia and osteoporosis) and had undergone DH for 1 year. At the arrival of all patients, BMD was checked with the DXA (dual-energy X-ray absorptiometry) method using the 2007 American Explorer model Hologic device based on the Caucasian race. One year later, patients were reassessed for BMD by the same device.
Result
The analysis of femoral neck (FN) and lumbar spine (LS) T-score indices in the osteopenia and the osteoporosis groups showed reduction after DH, and the difference was statistically significant in both groups (
p
= 0.001). After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups (
p
= 0.001).
Conclusion
In general, it can be said that DH can reduce FN and LS T-scores. The results indicated a significant reduction in BMD after the DH period for both the osteoporosis and osteopenia groups in the early months. Also, the effect of DH in osteoporosis patients was more compared to the osteopenia individuals, which could have implications for their treatment approach, and also its effect on bone health.
Key Points
• The DH can reduce FN and LS T-scores
• The BMD reduced after the DH period for both the osteoporosis and osteopenia groups
• After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups</description><subject>Alendronic acid</subject><subject>Bisphosphonates</subject><subject>Bone density</subject><subject>bone health</subject><subject>Bone mineral density</subject><subject>drugs</subject><subject>Dual energy X-ray absorptiometry</subject><subject>femur</subject><subject>Fractures</subject><subject>lumbar spine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Article</subject><subject>Osteopenia</subject><subject>Osteoporosis</subject><subject>Post-menopause</subject><subject>postmenopause</subject><subject>Rheumatology</subject><subject>risk</subject><subject>Spine (lumbar)</subject><subject>Statistical analysis</subject><issn>0770-3198</issn><issn>1434-9949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNqFksGOFCEURStG47SjP-DCkLiZTemjKKBYmo6OJpO40XWFglfdTLqgBCqT_pv5DNd-mfRUq4kLXQDhvXMvAW5VvaTwhgLIt6nMQtbQtDUIBaKWj6oNbVlbK9Wqx9UGpISaUdVdVM9SugWAplP0aXXBOtZK1vBN9X0bpllHl4InYSRD8Egm5zHqA7Hok8vHUz2kjGEOMWRniPb2XEDvNJnQh1kvqSjuQtmQHFFntOTO5T0JJ6fBpXkfTsOXTiIDjiEiSTnMs_M7kve4qoo8P_jTH_dH1JHoMWMkNi47sg8HZ_WRzBhdsM-rJ6M-JHxxXi-rrx_ef9l-rG8-X3_avrupDeMq15wz03KNrZUGOFDFQbR80EZLoAYpGGHHRqHohOF0YGLUTA2sbcCKkTHDLqur1XeO4duCKfeTSwYPB-0xLKlnlDNBy7vy_6KNagTIDpQq6Ou_0NuwRF8uUijeUegYawvVrJSJIaWIYz9HN-l47Cn0pwj0awT6EoH-IQK9LKJXZ-tlmND-lvz68wKwFUil5XcY_5z9D9ufkP3AyQ</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Rizi, Marzieh Moradi</creator><creator>Salari, Amirhossein</creator><creator>Salesi, Mansour</creator><creator>Rasooli, Laa’ya</creator><creator>Karimifar, Mansoor</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0003-4688-991X</orcidid><orcidid>https://orcid.org/0000-0001-7108-6188</orcidid><orcidid>https://orcid.org/0000-0001-7077-9652</orcidid><orcidid>https://orcid.org/0000-0002-7542-7426</orcidid><orcidid>https://orcid.org/0000-0003-4860-1174</orcidid></search><sort><creationdate>20240401</creationdate><title>Comparison of bone mineral density of osteoporotic and osteopenia menopausal women treated with oral bisphosphonates before stopping the treatment and 1 year after drug holiday period</title><author>Rizi, Marzieh Moradi ; Salari, Amirhossein ; Salesi, Mansour ; Rasooli, Laa’ya ; Karimifar, Mansoor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-553c45ae4d7c0501950645baca701ce10c6df29e686c51b36fa39b3420d6f33c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alendronic acid</topic><topic>Bisphosphonates</topic><topic>Bone density</topic><topic>bone health</topic><topic>Bone mineral density</topic><topic>drugs</topic><topic>Dual energy X-ray absorptiometry</topic><topic>femur</topic><topic>Fractures</topic><topic>lumbar spine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Article</topic><topic>Osteopenia</topic><topic>Osteoporosis</topic><topic>Post-menopause</topic><topic>postmenopause</topic><topic>Rheumatology</topic><topic>risk</topic><topic>Spine (lumbar)</topic><topic>Statistical analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rizi, Marzieh Moradi</creatorcontrib><creatorcontrib>Salari, Amirhossein</creatorcontrib><creatorcontrib>Salesi, Mansour</creatorcontrib><creatorcontrib>Rasooli, Laa’ya</creatorcontrib><creatorcontrib>Karimifar, Mansoor</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Clinical rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rizi, Marzieh Moradi</au><au>Salari, Amirhossein</au><au>Salesi, Mansour</au><au>Rasooli, Laa’ya</au><au>Karimifar, Mansoor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of bone mineral density of osteoporotic and osteopenia menopausal women treated with oral bisphosphonates before stopping the treatment and 1 year after drug holiday period</atitle><jtitle>Clinical rheumatology</jtitle><stitle>Clin Rheumatol</stitle><addtitle>Clin Rheumatol</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>43</volume><issue>4</issue><spage>1375</spage><epage>1379</epage><pages>1375-1379</pages><issn>0770-3198</issn><eissn>1434-9949</eissn><abstract>Background
Osteoporosis is a skeletal and bone disorder characterized by bone fractures and decreased bone mineral density (BMD). Bisphosphonates have a great tendency to bind to minerals, and their long-term use can increase the risk of bone fragility in patients. Stopping bisphosphonates after a period of time is called a drug holiday (DH). Recent evidence has shown that patients’ BMD may decrease again during DH. However, few studies have been done in this regard. In the present study, we compared the BMD of postmenopausal women during bisphosphonates treatment and 1 year after DH.
Material and methods
A total of 202 patients were selected with osteopenia (
n
= 95) and osteoporosis (
n
= 107); they had been treated with alendronate for 5 years (a rheumatologist confirmed the diagnosis of osteopenia and osteoporosis) and had undergone DH for 1 year. At the arrival of all patients, BMD was checked with the DXA (dual-energy X-ray absorptiometry) method using the 2007 American Explorer model Hologic device based on the Caucasian race. One year later, patients were reassessed for BMD by the same device.
Result
The analysis of femoral neck (FN) and lumbar spine (LS) T-score indices in the osteopenia and the osteoporosis groups showed reduction after DH, and the difference was statistically significant in both groups (
p
= 0.001). After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups (
p
= 0.001).
Conclusion
In general, it can be said that DH can reduce FN and LS T-scores. The results indicated a significant reduction in BMD after the DH period for both the osteoporosis and osteopenia groups in the early months. Also, the effect of DH in osteoporosis patients was more compared to the osteopenia individuals, which could have implications for their treatment approach, and also its effect on bone health.
Key Points
• The DH can reduce FN and LS T-scores
• The BMD reduced after the DH period for both the osteoporosis and osteopenia groups
• After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>38347325</pmid><doi>10.1007/s10067-024-06906-7</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-4688-991X</orcidid><orcidid>https://orcid.org/0000-0001-7108-6188</orcidid><orcidid>https://orcid.org/0000-0001-7077-9652</orcidid><orcidid>https://orcid.org/0000-0002-7542-7426</orcidid><orcidid>https://orcid.org/0000-0003-4860-1174</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0770-3198 |
| ispartof | Clinical rheumatology, 2024-04, Vol.43 (4), p.1375-1379 |
| issn | 0770-3198 1434-9949 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2926078099 |
| source | Springer Journals |
| subjects | Alendronic acid Bisphosphonates Bone density bone health Bone mineral density drugs Dual energy X-ray absorptiometry femur Fractures lumbar spine Medicine Medicine & Public Health Original Article Osteopenia Osteoporosis Post-menopause postmenopause Rheumatology risk Spine (lumbar) Statistical analysis |
| title | Comparison of bone mineral density of osteoporotic and osteopenia menopausal women treated with oral bisphosphonates before stopping the treatment and 1 year after drug holiday period |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T20%3A46%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20bone%20mineral%20density%20of%20osteoporotic%20and%20osteopenia%20menopausal%20women%20treated%20with%20oral%20bisphosphonates%20before%20stopping%20the%20treatment%20and%201%C2%A0year%20after%20drug%20holiday%20period&rft.jtitle=Clinical%20rheumatology&rft.au=Rizi,%20Marzieh%20Moradi&rft.date=2024-04-01&rft.volume=43&rft.issue=4&rft.spage=1375&rft.epage=1379&rft.pages=1375-1379&rft.issn=0770-3198&rft.eissn=1434-9949&rft_id=info:doi/10.1007/s10067-024-06906-7&rft_dat=%3Cproquest_cross%3E2958108334%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2958108334&rft_id=info:pmid/38347325&rfr_iscdi=true |